Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
DSM, Crucell increasing PER.C6 yields
Volgen
GET RID OF RON AND STOCK GOES TO 40 EURO!!!
Natuurlijk is er een milestone ontvangen van Sanofi na afloop van fase 1. Alleen niet gemeld. En zou er dan wéééééér een milestone moeten komen bij de start van fase 2???? Onzin!!
oudje schreef:
Natuurlijk is er een milestone ontvangen van Sanofi na afloop van fase 1. Alleen niet gemeld.
En zou er dan wéééééér een milestone moeten komen bij de start van fase 2???? Onzin!!
Let's see, no milestone for completion of phase I, and no milestone for the start of phase II, but you claim there is a milestone. And Crucell, using the "Cone of Silence" from Get Smart, claims it is not allowed to ever say anything about milestones...ever. Which in this case is easy, because there isn't one. Oudje, call Ron and Leon and tell them you need more money to so shamelessly pump this stock. Since Ron and Leon have shown such lax moral ethics, they might agree to throw an extra couple hundred a month your way. Then you can at least be an Overpaid Pumper.
ron banged schreef:
[quote=oudje]
Natuurlijk is er een milestone ontvangen van Sanofi na afloop van fase 1. Alleen niet gemeld.
En zou er dan wéééééér een milestone moeten komen bij de start van fase 2???? Onzin!!
[/quote]
Let's see, no milestone for completion of phase I, and no milestone for the start of phase II, but you claim there is a milestone. And Crucell, using the "Cone of Silence" from Get Smart, claims it is not allowed to ever say anything about milestones...ever. Which in this case is easy, because there isn't one.
Oudje, call Ron and Leon and tell them you need more money to so shamelessly pump this stock. Since Ron and Leon have shown such lax moral ethics, they might agree to throw an extra couple hundred a month your way. Then you can at least be an Overpaid Pumper.
Ron, you are out of line!
ron banged schreef:
[quote=oudje]
Natuurlijk is er een milestone ontvangen van Sanofi na afloop van fase 1. Alleen niet gemeld.
En zou er dan wéééééér een milestone moeten komen bij de start van fase 2???? Onzin!!
[/quote]
Let's see, no milestone for completion of phase I, and no milestone for the start of phase II, but you claim there is a milestone. And Crucell, using the "Cone of Silence" from Get Smart, claims it is not allowed to ever say anything about milestones...ever. Which in this case is easy, because there isn't one.
Oudje, call Ron and Leon and tell them you need more money to so shamelessly pump this stock. Since Ron and Leon have shown such lax moral ethics, they might agree to throw an extra couple hundred a month your way. Then you can at least be an Overpaid Pumper.
Ronnie , I agree: You have the chart on your site. Again , the chart breaks downward. Help help help, we can't swimm.
Hier begint maag werkelijk van te draaien.....wat een inspelen op de koersontwikkeling van vandaag, bah!
Cybertom schreef:
Hier begint maag werkelijk van te draaien.....wat een inspelen op de koersontwikkeling van vandaag, bah!
Niet bepaald inspelen op de koersontwikkeling, dan heb je het verkeerd. De totale markt staat wederom op een draaipunt. Als jij het NIET vreemd vindt dat de koers wederom fors onderuit gaat . 10% eraf betekent niets? En voor de niet? wetenden : er zijn weer turbo's , speeders van 7, nl 7,8,9,10,11 allen long , en geen shorts erbij. Zegt dat dan niet voldoende?
www.dsm.com/en_US/downloads/invest/an... Embracing the Future DSM Pharmaceutical Products and Crucell have jointly developed the XD™ process, involving a highdensity cell culture with (human) PER.C6® cells. This innovation is based on clever design of the cell-culture processing equipment and can lead to a paradigm shift in the manufacturing of complex, costly biopharmaceuticals such as recombinant proteins including monoclonal antibodies. This achievement represents another step forward in the establishment of the PER.C6® protein manufacturing platform, jointly developed by Crucell and DSM, as the leading (human) technology in the industry and will make biopharmaceuticals cheaper and therefore available to a much wider patient population than today. In addition, the human PER.C6® cells have the potential to bestow beneficial properties on the biopharmaceuticals they are programmed to produce, and minimize side effects potentially associated ith the use of non-human cell systems. In 2007, a yield of 13 grams per liter was achieved for XD™ and PER.C6®. DSM Biologics is a provider of biopharmaceutical manufacturing technology and services. DSM iologics and Crucell NV have co-exclusive rights to license the highproducing PER.C6 ® technology platform to the biopharmaceutical industry as a production platform for recombinant proteins and monoclonal antibodies. DSM Biologics operates a manufacturing facility in Groningen, the Netherlands, approved by the US Food and Drug Administration (FDA) for mammalian-cell-based ontract manufacturing and PER.C6 ® process support. DSM Biologics also offers microbial-cell-based contract manufacturing services through its operations in Capua, Italy. Anti-Infectives R&D successfully scaled up cophenolate mofetil. Registration batches were produced and first sales realized. Pharmaceutical Products R&D developed the XD™ process , involving a high-cell-density cell culture with human PER.C6® cells. DSM Biologics’ activities were centered on providing manufacturing services for new and existing customers from the facility in Groningen (Netherlands) and expanding the PER.C6 ® Development Center in Boston, United States with joint-venture partner Crucell NV. The number of new manufacturing projects increased compared with 2006. DSM Biologics also announced the innovative XD ™ process . This cell-based manufacturing process tailored to the PER.C6 ® technology platform is capable of producing much higher yields in manufacturing, and can create a breakthrough in biopharmaceutical manufacturing.
(WO/2008/006494) IMPROVED PROCESS FOR THE CULTURING OF CELLS Applicants: DSM IP ASSETS B.V. [NL/NL]; Agent: BREEPOEL, Peter, Maria; DSM Intellectual Property Abstract: The invention relates to a process for the culturing of cells, preferably E1-immortalized HER cells, more preferably PER.C6 cells in a reactor in suspension in a cell culture medium, wherein the cells produce a biological substance, preferably an antibody, wherein at least one cell culture medium component is fed to the cell culture and wherein the cell culture comprising the cells, the biological substance and cell culture medium is circulated over a separation system and wherein the separation system separates the biological substance from substances having a lower molecular weight than the biological substance and wherein the biological substance is retained in or fed back into the reactor. Preferably part of the substances of lower molecular weight is continuously removed from the cell culture. www.wipo.int/patentscopedb/en/fetch.j...
Mooi linkje go, even wennen aan de DSM-namen! The invention relates to a process for the culturing of cells in a reactor in suspension in a cell culture medium. Such a process is for example known from WO04/099396. Herein it is described how the cell density of the cell culture and the yield of the desired biological material can be improved by optimizing the growth conditions in a fed-batch process. Furthermore, WO05/095578 discloses a process for the culturing of cells by continuous perfusion culturing of a cell culture comprising cell culture medium and cells, wherein cell culture medium is added to the cell culture, the cell culture is circulated over a filter module comprising hollow fibers resulting in an outflow of liquid having a lower cell density than the cell culture, and the flow within the filter module is an alternating tangential flow, wherein the cells produce a biological substance. In the examples of WO05/095578 it is shown that 0.9 g/L/day product is produced, corresponding to a product concentration in the outflow of approximately 0.3 g/L. The larger the volume of liquid containing the biological substance, the more laborious becomes the purification of the biological substance. The concentration of biological substance obtained is not that high in the processes as disclosed in WO04/099396 and WO05/095578. Therefore, downstream processing of this biological substance is cumbersome, because the biological substance needs to be concentrated before further purification steps are applied or large volumes of less concentrated biological substance need to be purified. Furthermore, the culturing of cells at lower cell densities results in lower volumetric productivity and therefore requires larger and/or more culturing vessels and thus higher investments in equipment for a given production level. Therefore, it is the object of the invention to provide a process wherein the product is obtained from the cell culture in higher concentrations. A further object of the present invention is to enable culturing of the cells and production of the biological material during an extended period. These objects are achieved by a process for the culturing of cells in a reactor in suspension in a cell culture medium, wherein the cells produce a biological substance, wherein at least one cell culture medium component is fed to the cell culture and wherein the cell culture comprising the biological substance and cell culture is circulated over a separation system and wherein the separation system separates the biological substance from substances having a lower molecular weight than the biological substance and wherein the biological substance is retained in or fed back into the reactor. For example, the invention relates to a process for the culturing of cells in a reactor in a cell culture medium, wherein the cells produce a biological substance, wherein nutrients and/or cell culture medium is/are fed to the reactor and wherein the cell culture comprising the cells and the cell culture medium is circulated over a filter having a pore size or molecular weight cut off of between 5 and 50OkD. It has been found that by using a separation system that separates the biological substance from substances having a lower molecular weight than the biological substance, the biological substance can be accumulated in the cell culture in higher concentrations. Hence, the present invention differs form the cell culturing described in the prior art in that it allows for accumulation of the desired biological material together with the cell mass. In a preferred embodiment of the present invention part of the substances of lower molecular weight are continuously removed from the cell culture. An additional advantage of the process of the present invention is that higher viable cell concentration can be reached as compared to for example batch or fed-batch processes. Furthermore, the production time - the period during which the cells produce the biological substance - can be extended compared to for example batch or fed-batch processes. Also, as compared to a batch or fed-batch process, it is possible to use a smaller reactor. Use of smaller reactors is of advantage as this reduces the equipment and facility related investments. Also, higher concentrations of the biological substance may be obtained in shorter times. It was found that it was possible to obtain high concentrations of biological substance within the reactor without sharply decreasing the cell viability and hence without limiting the production time. The person skilled in the art would have expected that the product inhibition, i.e. inhibition of production of the biological substance by the biological substance itself or inhibition by other macromolecules produced by the cell (such as for instance host cell proteins, enzymes or cellular debris), would occur. Furthermore, it was found that the accumulation of the desired biological material does not impair the function of the separation system. The process of the present invention provides a considerable advantage in terms of cell density, product concentration in the cell culture and extended culturing period as compared to the processes according to WO05/095578 and WO04/099396. As a result the present process results in an improved production of the desired biological material. Cells which can be used to produce the biological substance are in principle all cells known to the person skilled in the art, which have the ability to produce a biological product. The cells may be eukaryotic, for example, filamentous fungi, for example Aspergillus niger, Aspergillus oryzae, Trichoderma reesei, Penicillium chrysogenum, yeasts, for example Saccharomyces cerevisiae, Kluyveromyces lactis, Phaffia rhodozyma, yeast from the genus Pichia, for example Pichia pastoris or prokaryotic, for instance Escherichia coli, Bacillus sp, for example B. licheniformis, B. subtilis, B. amyloliquefaciens, B. alkalophilus, Streptomyces sp. , Corynebacterium glutamicum, Pseudomonas sp. Examples of eukaryotic cells are for example also described in Chu, L., Robinson, D. K., (2001 ) Curr. Opinion Biotechn., vol. 12, p. 180-187. Preferably, the cells that are used in the process of the present invention are animal cells, in particular mammalian cells. Examples of mammalian cells include CHO (Chinese Hamster Ovary) cells, hybridomas, BHK (Baby Hamster Kidney) cells, myeloma cells, human cells, for example HEK-293 cells, human lymphoblastoid cells, E1 immortalized HER cells, mouse cells, for example NSO cells. More preferably, E1 immortalized HER cells are used, most preferably PER.C6 cells.
Oeps flosz, had je in boosheid en teleurstelling IEX er helemaal aan gegeven? IEX: strijk over je hart, en maak flosz weer flosz! Welcome back, anyway: het blijft inderdaad moeilijk kiezen, zeker gezien die verrekte internet-anonimiteit met telkens weer opduikende 'nieuwe' aliassen en betaalde 'leden, in dienst van...???'? In luttele jaren tijd is het er niet beter op geworden op fora als deze, integendeel. Maaarrr: wij zullen doorgaan!!!
josti5 schreef:
Maaarrr: wij zullen doorgaan!!!
Vooral omdat recent ook Brus wat heeft opgevist aan braderieprijzen. (+18076 stuks à EUR 9,1)
josti5 schreef:
Oeps flosz, had je in boosheid en teleurstelling IEX er helemaal aan gegeven?
IEX: strijk over je hart, en maak flosz weer flosz!
Hé J. Klopt. Is inmiddels gelukt(naam was in eerste instantie niet beschikbaar), ik weet nu ook dat het daadwerkelijk mogelijk is om via 2 "aliJasses" lid te zijn en in te loggen vanaf één comp./IP adr. Dus je hebt helemaal gelijk..., profjes kunnen dit ook met tig "aliJasses". Gr. Linkje bij post aossa:crucell.yourbb.nl/viewtopic.php?f=5&t...
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
876,56
-0,26%
EUR/USD
1,0700
-0,10%
FTSE 100
8.150,62
+0,36%
Germany40^
17.927,60
-0,03%
Gold spot
2.298,05
+0,54%
NY-Nasdaq Composite
15.605,48
-0,33%
Stijgers
Dalers